
**Clinical investigation of medical devices
for human subjects — Good clinical
practice**

*Investigation clinique des dispositifs médicaux pour sujets humains —
Bonnes pratiques cliniques*



PDF disclaimer

This PDF file may contain embedded typefaces. In accordance with Adobe's licensing policy, this file may be printed or viewed but shall not be edited unless the typefaces which are embedded are licensed to and installed on the computer performing the editing. In downloading this file, parties accept therein the responsibility of not infringing Adobe's licensing policy. The ISO Central Secretariat accepts no liability in this area.

Adobe is a trademark of Adobe Systems Incorporated.

Details of the software products used to create this PDF file can be found in the General Info relative to the file; the PDF-creation parameters were optimized for printing. Every care has been taken to ensure that the file is suitable for use by ISO member bodies. In the unlikely event that a problem relating to it is found, please inform the Central Secretariat at the address given below.



COPYRIGHT PROTECTED DOCUMENT

© ISO 2011

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying and microfilm, without permission in writing from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
Case postale 56 • CH-1211 Geneva 20
Tel. + 41 22 749 01 11
Fax + 41 22 749 09 47
E-mail copyright@iso.org
Web www.iso.org

Published in Switzerland

Contents

Page

| | |
|---|-----------|
| Foreword | v |
| 1 Scope | 1 |
| 2 Normative references | 1 |
| 3 Terms and definitions | 2 |
| 4 Ethical considerations | 7 |
| 4.1 General | 7 |
| 4.2 Improper influence or inducement | 8 |
| 4.3 Compensation and additional health care | 8 |
| 4.4 Responsibilities | 8 |
| 4.5 Communication with the ethics committee (EC) | 8 |
| 4.5.1 General | 8 |
| 4.5.2 Initial EC submission | 8 |
| 4.5.3 Information to be obtained from the EC | 9 |
| 4.5.4 Continuing communication with the EC | 9 |
| 4.5.5 Continuing information to be obtained from the EC | 9 |
| 4.6 Vulnerable populations | 9 |
| 4.7 Informed consent | 10 |
| 4.7.1 General | 10 |
| 4.7.2 Process of obtaining informed consent | 10 |
| 4.7.3 Special circumstances for informed consent | 10 |
| 4.7.4 Information to be provided to the subject | 11 |
| 4.7.5 Informed consent signature | 13 |
| 4.7.6 New information | 13 |
| 5 Clinical investigation planning | 14 |
| 5.1 General | 14 |
| 5.2 Risk evaluation | 14 |
| 5.3 Justification for the design of the clinical investigation | 14 |
| 5.4 Clinical investigation plan (CIP) | 14 |
| 5.5 Investigator's brochure (IB) | 15 |
| 5.6 Case report forms (CRFs) | 15 |
| 5.7 Monitoring plan | 15 |
| 5.8 Investigation site selection | 15 |
| 5.9 Agreement(s) | 15 |
| 5.10 Labelling | 15 |
| 5.11 Data monitoring committee (DMC) | 16 |
| 6 Clinical investigation conduct | 16 |
| 6.1 General | 16 |
| 6.2 Investigation site initiation | 16 |
| 6.3 Investigation site monitoring | 16 |
| 6.4 Adverse events and device deficiencies | 16 |
| 6.4.1 Adverse events | 16 |
| 6.4.2 Device deficiencies | 16 |
| 6.5 Clinical investigation documents and documentation | 17 |
| 6.5.1 Amendments | 17 |
| 6.5.2 Subject identification log | 17 |
| 6.5.3 Source documents | 17 |
| 6.6 Additional members of the investigation site team | 17 |
| 6.7 Subject privacy and confidentiality of data | 17 |
| 6.8 Document and data control | 18 |